Key Takeaways
- • Claret Capital Partners commits €43 million as part of a €130 million debt financing round for Inventiva, a French clinical-stage biopharmaceutical company, with an additional €20 million uncommitted tranche available.
- • Inventiva is advancing lanifibranor, an oral once-daily pan-PPAR agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), a progressive chronic liver disease, with Phase 3 NATiV3 trial top-line readout anticipated in Q4 2026.
- • The financing is co-led by funds and accounts managed by BlackRock alongside Claret Capital Partners, structured in committed tranches as part of Inventiva's comprehensive capital structure optimization announced June 2, 2026.
- • This investment represents Claret Capital's continued expansion in late-stage European biotech, building on its track record of €1.2 billion invested across more than 195 SMEs since 2013.
Summary
Claret Capital Partners, Europe's largest independent growth debt fund manager, has deployed €43 million into Inventiva, a Dijon-headquartered clinical biopharmaceutical company, as part of a €130 million debt financing facility. The capital injection was announced June 16, 2026, and follows Inventiva's broader capital structure optimization announcement on June 2, 2026. The financing includes committed tranches totaling €130 million, with an additional uncommitted tranche of up to €20 million available to the company.
The financing is jointly structured with funds and accounts managed by BlackRock, positioning two major institutional investors behind Inventiva's clinical development agenda. Inventiva is advancing lanifibranor, an oral once-daily pan-PPAR agonist designed to simultaneously activate all three subtypes of peroxisome proliferator-activated receptors (PPARs). The therapy targets metabolic, inflammatory, and fibrotic pathways in MASH, a progressive chronic liver disease characterized by fat accumulation that triggers chronic inflammation and hepatic scarring. The company is currently evaluating lanifibranor in the Phase 3 NATiV3 trial, with top-line results anticipated in the fourth quarter of 2026.
For Claret Capital, this investment continues its strategic pivot toward late-stage European biotech opportunities. The firm has deployed over €1.2 billion across more than 195 SMEs since its founding in 2013, and this Inventiva commitment signals accelerating activity in the life sciences sector. The debt financing structure—rather than traditional equity investment—provides Inventiva with growth capital while preserving equity for existing shareholders as the company approaches potential regulatory decision points. With Phase 3 data approaching in Q4 2026, the timing of this capital deployment aligns with Inventiva's clinical inflection points and potential market inflection for MASH therapeutics.
The financing is jointly structured with funds and accounts managed by BlackRock, positioning two major institutional investors behind Inventiva's clinical development agenda. Inventiva is advancing lanifibranor, an oral once-daily pan-PPAR agonist designed to simultaneously activate all three subtypes of peroxisome proliferator-activated receptors (PPARs). The therapy targets metabolic, inflammatory, and fibrotic pathways in MASH, a progressive chronic liver disease characterized by fat accumulation that triggers chronic inflammation and hepatic scarring. The company is currently evaluating lanifibranor in the Phase 3 NATiV3 trial, with top-line results anticipated in the fourth quarter of 2026.
For Claret Capital, this investment continues its strategic pivot toward late-stage European biotech opportunities. The firm has deployed over €1.2 billion across more than 195 SMEs since its founding in 2013, and this Inventiva commitment signals accelerating activity in the life sciences sector. The debt financing structure—rather than traditional equity investment—provides Inventiva with growth capital while preserving equity for existing shareholders as the company approaches potential regulatory decision points. With Phase 3 data approaching in Q4 2026, the timing of this capital deployment aligns with Inventiva's clinical inflection points and potential market inflection for MASH therapeutics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.